# FORM 4

1. Name and Address of Reporting Person\* **WONG RODERICK** 

C/O RTW INVESTMENTS, LP

(First)

(Middle)

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ox if no longer subject to	STATEMENT OF CHA

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Control of the

							(				1	t of 1940						
1. Name and Address of Reporting Person*  RTW INVESTMENTS, LP				<u>R0</u>	2. Issuer Name and Ticker or Trading Symbol ROCKET PHARMACEUTICALS, INC. [ RCKT ]								S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner  Officer (give title) Other (specify)					
(Last) (First) (Middle) 40 10TH AVENUE					of Earlie	est Tran	saction (M	1onth/	/Day/Year)		Officer (give title X Other (specify below)  See Remarks							
7TH FLOOR			4. 1										6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) NEW YORK NY 10014			-	Form filed by One Reporting Person  X Form filed by More than One Reporting Person											I			
City) (State) (Zip)			Ri	Rule 10b5-1(c) Transaction Indication														
						Che satis	ck this b fy the at	ox to inc	dicate that a e defense c	trans onditio	action was ons of Rule	made pursua 10b5-1(c). S	ee Instructio	act, instructio n 10.	n or writter	plan tha	t is intende	ed to
		Tal	ole I - No	n-Deri	vativ	e Se	curiti	es Ad	cquired	, Dis	sposed	of, or Be	neficiall	y Owned				
			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (I	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5			5. Amount of Securities Beneficially Owned Following Reported		Direct ndirect r. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	on(s)	(In		(Instr. 4)
Common Stock") <sup>(1)</sup>		01 par value ("C	ommon	08/28	3/2023				J/K <sup>(2)</sup>		500,00	00 A	\$22.05	18,65	7,605			See footnote <sup>(4)</sup>
Common	Stock <sup>(1)</sup>			08/28	3/2023				J/K <sup>(2)</sup>		500,00	00 D	\$15.87	18,15	18 157 605 T T			See footnote <sup>(4)</sup>
Common	Stock <sup>(1)</sup>	Stock <sup>(1)</sup> 08/28/20			3/2023	)23		J/K <sup>(3)</sup>		500,00	00 D	\$22.05	17,657,605				See footnote <sup>(4)</sup>	
Common	Stock <sup>(1)</sup>	Stock <sup>(1)</sup> 08/28.		3/2023	2023					500,00	00 A	\$15.87	18,15	7,605	605 I		See footnote <sup>(4)</sup>	
			Table II									f, or Ben ible sec		Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of E		Expiration	i. Date Exercisable expiration Date Month/Day/Year)		7. Title and of Securiti Underlying Derivative (Instr. 3 an	es   Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Beneficie Owned Followin Reporter Transact (Instr. 4)	re es ally g	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
				Ī												- 1		
					Code	v	(A)		Date Exercisab		expiration pate	Title	Amount or Number of Shares					
Equity Swap (obligation o buy) <sup>(1)</sup>	\$22.05	08/28/2023			Code J/K <sup>(2)</sup>	v	(A)			le D		Title  Common Stock	or Number	(2)	0		I	See footnote <sup>(4)</sup>
Swap obligation	\$22.05 \$22.05	08/28/2023 08/28/2023				v	(A)	(D)	Exercisab	8 0	ate	Common	or Number of Shares	(2)	0		I	
Swap obligation o buy) <sup>(1)</sup> Equity Swap obligation o sell) <sup>(1)</sup>	\$22.05 and Address o				J/K <sup>(2)</sup>	v	(A)	1	08/27/201	8 0	8/28/2023	Common Stock	or Number of Shares 500,000					footnote <sup>(4)</sup> See
Swap obligation o buy) <sup>(1)</sup> Equity Swap obligation o sell) <sup>(1)</sup> L. Name at RTW I	\$22.05  and Address of NVESTN  AVENUE	08/28/2023  f Reporting Person*	(Mid		J/K <sup>(2)</sup>	v	(A)	1	08/27/201	8 0	8/28/2023	Common Stock	or Number of Shares 500,000					footnote <sup>(4)</sup> See
Swap obligation o buy) <sup>(1)</sup> Equity Swap obligation o sell) <sup>(1)</sup> L. Name at RTW I (Last)	\$22.05  and Address of NVESTN  AVENUE OOR	08/28/2023  f Reporting Person*  MENTS, LP	(Mid	dle)	J/K <sup>(2)</sup>	v	(A)	1	08/27/201	8 0	8/28/2023	Common Stock	or Number of Shares 500,000					footnote <sup>(4)</sup> See

40 10TH AVENU	JE, 7TH FLOOR		
(Street) NEW YORK	NY	10014	
(City)	(State)	(Zip)	

### **Explanation of Responses:**

- 1. This Form 4 is being filed in connection with the equity swap transactions described below. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change.
- 2. On August 28, 2023, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Form 4 filed by the Reporting Persons on August 29, 2018 (the "2018 Form 4"), expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Innovation Master Fund, Ltd. into an equity swap (obligation to sell); RTW Innovation Master Fund, Ltd. in fact entered into an equity swap (obligation to buy).
- 3. On August 28, 2023, the equity swap entered into by RTW Master Fund, Ltd. previously reported on the 2018 Form 4, expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Master Fund, Ltd. into an equity swap (obligation to buy); RTW Master Fund, Ltd. in fact entered into an equity swap (obligation to sell).
- 4. This Form 4 is being filed by each of (i) RTW Investments, LP (the "Adviser") with respect to the securities held by certain investment funds managed by the Adviser (the "RTW Funds") and (ii) Roderick Wong, M.D. ("Dr. Wong"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors.

### Remarks:

The Adviser may be deemed to be a director by deputization for purposes of Section 16 under the Securities Exchange Act of 1934 by virtue of the fact that each of Dr. Wong, Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of the Adviser, and Gotham Makker, who serves as Head of Strategic Investments of the Adviser, currently serves on the board of directors of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The 2018 Form 4 reported an expiration date of the reported swaps of August 27, 2023; however the expiration date was in fact August 28, 2023.

RTW Investments, LP, By: /s/
Roderick Wong, Managing 08/30/2023

Partner

Roderick Wong, M.D., By: /s/
08/30/2023

\*\* Signature of Reporting Person Date

**Roderick Wong** 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.